

## EFFICACY OF LISDEXAMFETAMINE DIMESYLATE IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: EFFECT OF AGE, SEX AND BASELINE DISEASE SEVERITY

**M. Lecendreux**<sup>1</sup>, T. Banaschewski<sup>2</sup>, C. Soutullo<sup>3</sup>, M. Johnson<sup>4</sup>, A. Zuddas<sup>5</sup>, C. Anderson<sup>6</sup>, R. Civil<sup>6</sup>, N. Higgins<sup>6</sup>, R. Bloomfield<sup>7</sup>, L. Squires<sup>6</sup>, D. Coghill<sup>8</sup>

<sup>1</sup>Pediatric Sleep Center, CHU Robert Debré, Paris, France, <sup>2</sup>Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, <sup>3</sup>Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain, <sup>4</sup>Child Neuropsychiatry Unit, Queen Silvia Children's Hospital, Gothenburg, Sweden, <sup>5</sup>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy, <sup>6</sup>Shire Development LLC, Wayne, PA, USA, <sup>7</sup>Shire Pharmaceutical Development Ltd, Basingstoke, <sup>8</sup>Division of Neuroscience, Ninewells Hospital, Dundee, UK

**Introduction:** In a European, phase 3 study (SPD489-325), lisdexamfetamine dimesylate (LDX) was more effective than placebo in improving symptoms and global functioning in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

**Objectives and aims:** To evaluate the impact of age, sex and baseline disease severity on efficacy outcomes in SPD489-325.

**Methods:** This 7-week, double-blind, parallel-group, dose-optimized study enrolled patients aged 6-17 years with ADHD. Patients were randomized (1:1:1) to once-daily LDX (30, 50 or 70mg/day), osmotic-release oral system methylphenidate (OROS-MPH; 18, 36 or 54mg/day) or placebo. Efficacy outcomes were analysed in patients dichotomized by age (6-12 years [n=229] or 13-17 years [n=88]), sex (male [n=255] or female [n=62]) and baseline ADHD Rating Scale version IV (ADHD-RS-IV) total score (28-41 [n=161] or 42-54 [n=152]). Endpoint was the last on-treatment visit with a valid assessment.

**Results:** At endpoint, differences (active-placebo) in least-squares mean changes from baseline in ADHD-RS-IV total scores were statistically significant in all age, sex and ADHD-RS-IV total score subgroups for LDX ( $p < 0.001$ ; effect sizes, 1.68-2.26) and OROS-MPH ( $p < 0.01$ ; effect sizes, 0.88-1.46). Proportions of patients with a Clinical Global Impressions-Improvement rating of 1 (very much improved) or 2 (much improved) were statistically significantly greater than placebo at endpoint in all subgroups receiving LDX ( $p < 0.01$ ) and in all subgroups except females receiving OROS-MPH ( $p < 0.05$ ).

**Conclusions:** LDX showed greater efficacy than placebo in children and adolescents with ADHD, regardless of their age, sex or baseline disease severity.

**Supported by:** Funding from Shire Development LLC.